Hims & Hers Health (NYSE:HIMS) Trading Down 2.9% - What's Next?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price was down 2.9% on Friday . The stock traded as low as $48.87 and last traded at $49.92. Approximately 24,034,551 shares were traded during mid-day trading, an increase of 33% from the average daily volume of 18,134,518 shares. The stock had previously closed at $51.40.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on HIMS shares. Needham & Company LLC reiterated a "buy" rating and set a $61.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 6th. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and reduced their target price for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Truist Financial cut their price objective on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a report on Thursday, April 10th. Morgan Stanley reduced their price target on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 29th. Finally, Citigroup reaffirmed a "sell" rating and issued a $30.00 price objective (up previously from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and a consensus target price of $37.67.

Hims & Hers Health Trading Up 1.2 %

The firm has a market cap of $11.65 billion, a P/E ratio of 118.28 and a beta of 1.84. The firm has a 50-day simple moving average of $32.97 and a 200-day simple moving average of $32.43.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. During the same period last year, the firm earned $0.05 earnings per share. Hims & Hers Health's revenue was up 110.7% compared to the same quarter last year. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 2,203 shares of the stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the transaction, the insider now owns 8,007 shares in the company, valued at approximately $230,441.46. This represents a 21.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Melissa Baird sold 33,333 shares of Hims & Hers Health stock in a transaction on Monday, April 21st. The shares were sold at an average price of $25.78, for a total transaction of $859,324.74. Following the completion of the sale, the chief operating officer now directly owns 805,083 shares in the company, valued at $20,755,039.74. This represents a 3.98 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 650,500 shares of company stock worth $25,790,311. Company insiders own 13.71% of the company's stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. Farallon Capital Management LLC grew its position in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after acquiring an additional 8,364,000 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after buying an additional 2,020,722 shares during the period. Yong Rong HK Asset Management Ltd purchased a new position in Hims & Hers Health during the fourth quarter worth about $41,104,000. Finally, Renaissance Technologies LLC increased its position in shares of Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after acquiring an additional 1,562,302 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.